"Lymphoma, Mantle-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
Descriptor ID |
D020522
|
MeSH Number(s) |
C04.557.386.480.525 C15.604.515.569.480.525 C20.683.515.761.480.525
|
Concept/Terms |
Lymphoma, Mantle-Cell- Lymphoma, Mantle-Cell
- Lymphoma, Mantle Cell
- Lymphomas, Mantle-Cell
- Mantle-Cell Lymphomas
- Lymphocytic Lymphoma, Diffuse, Poorly Differentiated
- Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated
- Mantle-Zone Lymphoma
- Lymphoma, Mantle-Zone
- Lymphomas, Mantle-Zone
- Mantle Zone Lymphoma
- Mantle-Zone Lymphomas
- Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated
- Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated
- Lymphoma, Small-Cell, Centrocytic
- Mantle-Cell Lymphoma
- Mantle Cell Lymphoma
- Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
- Diffuse Lymphocytic Lymphoma, Poorly Differentiated
- Lymphoma, Centrocytic Small-Cell
- Centrocytic Small-Cell Lymphoma
- Centrocytic Small-Cell Lymphomas
- Lymphoma, Centrocytic Small Cell
- Lymphomas, Centrocytic Small-Cell
- Small-Cell Lymphoma, Centrocytic
- Small-Cell Lymphomas, Centrocytic
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Mantle-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Mantle-Cell".
This graph shows the total number of publications written about "Lymphoma, Mantle-Cell" by people in this website by year, and whether "Lymphoma, Mantle-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2006 | 1 | 0 | 1 |
2009 | 2 | 0 | 2 |
2010 | 1 | 1 | 2 |
2011 | 1 | 1 | 2 |
2012 | 1 | 0 | 1 |
2013 | 3 | 0 | 3 |
2015 | 2 | 0 | 2 |
2016 | 1 | 0 | 1 |
2017 | 1 | 1 | 2 |
2018 | 1 | 0 | 1 |
2019 | 0 | 1 | 1 |
2020 | 3 | 0 | 3 |
2021 | 4 | 0 | 4 |
2023 | 2 | 0 | 2 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, Mantle-Cell" by people in Profiles.
-
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024 Jul 09; 8(13):3528-3531.
-
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 07 11; 7(13):2983-2993.
-
Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec; 23(7):773-787.
-
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol. 2021 12; 195(5):757-763.
-
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 11; 27(11):911.e1-911.e7.
-
Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation. Am J Surg Pathol. 2021 07 01; 45(7):939-944.
-
Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. Blood Adv. 2021 01 12; 5(1):185-197.
-
An update on options of therapy for aggressive mantle cell lymphoma. Leuk Lymphoma. 2020 09; 61(9):2036-2049.
-
Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020 08; 59(8):484-494.
-
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020 06; 95(6):583-593.